Oncolytics Financial Statements From 2010 to 2025

ONC Stock  CAD 0.91  0.01  1.11%   
Oncolytics Biotech financial statements provide useful quarterly and yearly information to potential Oncolytics Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Oncolytics Biotech financial statements helps investors assess Oncolytics Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Oncolytics Biotech's valuation are summarized below:
Market Capitalization
78.6 M
Earnings Share
(0.41)
We have found one hundred twenty available trending fundamental ratios for Oncolytics Biotech, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Oncolytics Biotech's recent fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 16th of March 2025, Market Cap is likely to grow to about 137.3 M. Also, Enterprise Value is likely to grow to about 118 M

Oncolytics Biotech Total Revenue

0.0

Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 69.3 K, Interest Expense of 637.6 K or Selling General Administrative of 13.6 M, as well as many indicators such as Price To Sales Ratio of 66.83, Ptb Ratio of 5.18 or Days Sales Outstanding of 3.7. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
  
This module can also supplement various Oncolytics Biotech Technical models . Check out the analysis of Oncolytics Biotech Correlation against competitors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

Oncolytics Biotech Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30.1 M20.2 M25.8 M
Slightly volatile
Short and Long Term Debt Total301.2 K486.4 K459.2 K
Very volatile
Total Current Liabilities4.1 M6.7 M4.7 M
Very volatile
Property Plant And Equipment Net664.5 K1.3 M562 K
Slightly volatile
Accounts PayableM1.1 M2.8 M
Slightly volatile
Cash19.3 M15.9 M20.4 M
Pretty Stable
Non Current Assets Total1.8 M1.3 M853.9 K
Pretty Stable
Cash And Short Term Investments26.6 M40.1 M24.4 M
Slightly volatile
Net Receivables16.4 K17.2 K578.9 K
Very volatile
Common Stock Shares Outstanding80.9 M77.1 M30.5 M
Slightly volatile
Liabilities And Stockholders Equity30.5 M44.6 M27.3 M
Slightly volatile
Other Current Assets3.9 M3.7 M1.6 M
Slightly volatile
Other Stockholder Equity42.9 M48.4 M30 M
Slightly volatile
Total Liabilities14.9 M14.2 M8.7 M
Slightly volatile
Property Plant And Equipment GrossM1.9 M731 K
Slightly volatile
Total Current Assets27.7 M18.9 M24.9 M
Slightly volatile
Intangible Assets154.5 K162.7 K326.8 K
Slightly volatile
Short Term Investments2.9 MM7.7 M
Pretty Stable
Common Stock310.7 M495.5 M297.6 M
Slightly volatile
Common Stock Total Equity294.9 M410.3 M286.6 M
Slightly volatile
Property Plant Equipment610.4 K749.8 K572.4 K
Slightly volatile
Capital Surpluse35.9 M46.1 M32.1 M
Slightly volatile
Cash And Equivalents14.1 M13.4 M4.4 M
Slightly volatile
Other Liabilities6.9 M7.7 M5.7 M
Slightly volatile
Non Current Liabilities Other44.8 K47.2 K2.3 M
Slightly volatile
Net Working Capital11.6 M12.2 M17.6 M
Slightly volatile
Capital Stock411.3 M438.2 M331.9 M
Slightly volatile
Capital Lease Obligations627.6 K1.1 M537.9 K
Slightly volatile

Oncolytics Biotech Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization69.3 K72.9 K189.2 K
Slightly volatile
Selling General Administrative13.6 M12.9 M6.6 M
Slightly volatile
Other Operating Expenses19.5 M38.9 M22.6 M
Slightly volatile
Research Development13.1 M21.6 M14.4 M
Very volatile
Total Operating Expenses19.9 M35 M22.4 M
Slightly volatile
Interest Income1.8 M1.2 M1.2 M
Pretty Stable
Net Interest Income1.3 M1.2 M385.1 K
Slightly volatile
Reconciled Depreciation383.5 K424 K238 K
Slightly volatile
Selling And Marketing Expenses18.9 M18 M4.6 M
Slightly volatile

Oncolytics Biotech Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow18.6 M34.9 M21.5 M
Pretty Stable
Depreciation301.8 K424 K245.8 K
Slightly volatile
Capital Expenditures210.4 K239 K124.7 K
Very volatile
Total Cash From Financing Activities6.3 M6.6 M17.6 M
Pretty Stable
End Period Cash Flow19.3 M15.9 M20.4 M
Pretty Stable
Stock Based Compensation1.7 M2.7 M1.5 M
Slightly volatile
Sale Purchase Of Stock10.3 K10.8 K11.6 M
Slightly volatile
Issuance Of Capital Stock6.6 M6.9 M16.6 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio66.8370.342.7 M
Slightly volatile
Days Sales Outstanding3.73.8913.3585
Slightly volatile
Average Payables325.5 K342.6 K2.3 M
Slightly volatile
Stock Based Compensation To Revenue0.120.140.148
Slightly volatile
Capex To Depreciation0.540.56371.4828
Slightly volatile
EV To Sales62.4865.762.5 M
Slightly volatile
Inventory Turnover127142155
Slightly volatile
Sales General And Administrative To Revenue0.120.140.148
Slightly volatile
Research And Ddevelopement To Revenue13.117.447.2874
Very volatile
Capex To Revenue0.02850.030.0346
Slightly volatile
Cash Per Share0.620.651.9074
Slightly volatile
Days Payables Outstanding1.1 K1.1 K3.4 K
Pretty Stable
Income Quality0.710.85040.8923
Pretty Stable
Intangibles To Total Assets0.01410.01490.0347
Slightly volatile
Net Debt To EBITDA1.521.181.4309
Slightly volatile
Current Ratio2.682.82269.2151
Slightly volatile
Capex Per Share1.0E-41.0E-40.0101
Slightly volatile
Graham Net Net0.440.461.4873
Slightly volatile
Average Receivables66.7 K40.3 K69.1 K
Pretty Stable
Revenue Per Share0.570.550.5621
Slightly volatile
Interest Debt Per Share0.00680.00720.0317
Slightly volatile
Debt To Assets0.05530.05270.0255
Pretty Stable
Payables Turnover0.320.3425.2811
Pretty Stable
Receivables Turnover10297.08100
Slightly volatile
Days Of Payables Outstanding1.1 K1.1 K3.4 K
Pretty Stable
Ebt Per Ebit0.80.740.9653
Pretty Stable
Long Term Debt To Capitalization0.00890.00560.0062
Slightly volatile
Total Debt To Capitalization0.0880.1510.735
Slightly volatile
Quick Ratio2.682.82269.2151
Slightly volatile
Net Income Per E B T0.810.90.9984
Pretty Stable
Cash Ratio2.262.3848.2309
Slightly volatile
Days Of Sales Outstanding3.73.8913.3585
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00891.0158
Pretty Stable
Debt Ratio0.05530.05270.0255
Pretty Stable
Price Sales Ratio66.8370.342.7 M
Slightly volatile
Fixed Asset Turnover11.210.6710.9989
Slightly volatile
Asset Turnover0.210.20.2042
Slightly volatile

Oncolytics Biotech Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap137.3 M135.9 M118.5 M
Pretty Stable
Enterprise Value118 M96.2 M96.8 M
Pretty Stable

About Oncolytics Biotech Financial Statements

Oncolytics Biotech investors utilize fundamental indicators, such as revenue or net income, to predict how Oncolytics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-973.8 K-925.1 K
Cost Of Revenue362.7 K344.6 K
Stock Based Compensation To Revenue 0.14  0.12 
Sales General And Administrative To Revenue 0.14  0.12 
Research And Ddevelopement To Revenue 7.44  13.11 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.55  0.57 
Ebit Per Revenue(6.81)(7.15)

Pair Trading with Oncolytics Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Oncolytics Stock

  0.83JNJ Johnson Johnson CDRPairCorr
  0.8BRK Berkshire Hathaway CDRPairCorr
  0.75IBM International BusinessPairCorr
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:
Check out the analysis of Oncolytics Biotech Correlation against competitors.
To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.